Nomlabofusp pursues accelerated FDA approval in Friedreich's ataxia via frataxin surrogate endpoint — the bet is whether the BLA converts to full approval

Bull

A clean BLA submission accepted for review with a standard PDUFA date would validate the surrogate endpoint strategy and signal FDA confidence in the exposure-response analytical approach; combined with the Breakthrough Therapy Designation and written FDA guidance on submission elements, acceptance would substantially de-risk the path to accelerated approval and create a clear line of sight to U.S. commercialization in a rare, underserved disease with no approved frataxin-replacement therapy.

Bear

FDA could issue a Refuse to File letter or request substantial additional data if reviewers are not satisfied with the skin frataxin surrogate endpoint package, the open-label study topline data released in Q2 2026 shows inconsistency or a weaker effect size than prior readouts, or the exposure-response modeling is deemed insufficient — any of these outcomes would delay or derail the accelerated approval pathway entirely and force reliance on the Phase 3 confirmatory study for any approval.